Bayer Stock Quietly Gains as a Daunting Calendar of Court Rulings and Trade Risks Approaches

Bayer completes $2.45B eye drug deal, faces Supreme Court glyphosate ruling, J&J lawsuit, US trade probe; stock rises 4.36% to €37.81 ahead of Q2 results.

Bayer has closed a $2.45 billion biotech wager, launched a legal challenge against a rival, and found itself caught in a new Washington trade probe — yet the stock is barely budging. The shares have crept up 4.36 percent over the past week to close at €37.81, just above the 50-day moving average, but with a Supreme Court ruling on glyphosate liability due by end of June and second-quarter results set for August 4, the next few weeks could define the rest of the year.

A $300 Million Bet on the Eye

The Perfuse Therapeutics acquisition, completed on June 17, cost Bayer $300 million upfront but could reach $2.45 billion if development milestones are met. The prize is PER-001, an intravitreal implant in Phase II trials targeting glaucoma and diabetic retinopathy. The deal adds a potential blockbuster to Bayer’s ophthalmology pipeline, which already includes the recently launched Lynkuet.

Legacy Costs Cast a Long Shadow

While the Perfuse deal shows where Bayer wants to go, the Monsanto inheritance keeps pulling it back. The company expects cash outflows of roughly €5 billion in 2026 from glyphosate litigation alone, enough to push net financial debt to €32–33 billion and keep free cash flow negative. A US Supreme Court decision on federal pre-emption of warning-label claims — expected before end of June — could either cap or expand Bayer’s liability. More than 100 objections to a proposed class settlement currently pending in a Missouri court add further uncertainty.

A Three-Front Legal and Regulatory Storm

Bayer is also fighting on two other fronts. In February it sued Johnson & Johnson over advertising claims for the prostate cancer drug Erleada, which J&J says reduces the risk of death by 51 percent versus Bayer’s Nubeqa. Bayer argues that the claim relies on flawed retrospective analysis, not controlled trials. A US judge denied Bayer’s request for a preliminary injunction in April, and the case continues.

On the regulatory side, the US Trade Representative launched a Section 301 investigation on June 18 into Germany’s drug pricing policies, alleging discrimination against American exporters. As Germany’s largest pharmaceutical company, Bayer is effectively in the crosshairs — a new headwind just as the group is trying to de-risk its outlook.

Operational Progress Beneath the Noise

Despite the legal overhang, Bayer’s operating performance is showing genuine improvement. First-quarter figures confirmed the full-year currency-adjusted guidance, and the pharma pipeline is gaining heft with Nubeqa, Kerendia, and Lynkuet. The company is also leaning into artificial intelligence: a flagship production facility in Leverkusen is expected to cut costs by 8 to 12 percent, targeting €800 million to €1.2 billion in additional gross profit within five years.

In agriculture, Bayer unveiled the low-stature corn system “Preceon” at Expoagro 2026 in Argentina, aiming for a market launch this year. Its digital platform PRO Carbono now links around 3,000 producers engaged in regenerative farming — a small but strategically important shift toward sustainability-linked revenue.

Stock Picture: Gains Without Conviction

The shares are up roughly 43 percent over twelve months but still sit about 24 percent below the 52-week high near €50 set in February. The RSI of 53.6 indicates neutral momentum, while annualised volatility of 31.47 percent underscores how quickly sentiment can shift. The appointment of Dr. Judith Hartmann as CFO on June 1 brings fresh leadership to the finance function during a pivotal transformation.

For now, Bayer is a story of fundamental improvement struggling to break free from the legal and regulatory constraints that bind it. The Supreme Court decision and the Q2 report will show whether the recovery has enough momentum to overcome the headwinds — or whether the shares will remain stuck in neutral.